Crosstalk along the gut-liver axis modulates glutathione and cadmium-induced hepatotoxicity.

The natural flavonoid morin demonstrates promise as a dual-function agent against hepatocellular carcinoma (HCC) and chronic liver disease. Preclinical studies indicate it counteracts toxin-induced liver injury by modulating oxidative stress and inflammation via pathways like Nrf2/HO-1 and NF-κB. In HCC, morin enhances the efficacy of cisplatin by suppressing PARP1-mediated protective autophagy and DNA repair, while concurrently mitigating the drug's nephrotoxic side effects. This capacity to simultaneously combat tumor progression and protect normal tissues positions morin as a versatile therapeutic candidate. Its clinical translation will require formal validation in human studies and the development of advanced delivery systems to overcome restrictions in bioavailability.